This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, R. R. Articles by Mason, D. T. Search for Related Content PubMed PubMed Citation Articles by Miller, R. R. Articles by Mason, D. T.

Circulation, Vol 55, 881-884, Copyright © 1977 by American Heart Association

ARTICLES

Combined dopamine and nitroprusside therapy in congestive heart failure. Greater augmentation of cardiac performance by addition of inotropic stimulation to afterload reduction

RR Miller, NA Awan, JA Joye, KS Maxwell, AN DeMaria, EA Amsterdam and DT Mason

The hemodynamic benefits of combining administration of dopamine with nitroprusside (NP) were evaluated in nine patients with chronic congestive heart failure due to ischemic, idiopathic myocardial or valvular cardiac disease. NP alone (68 microng/min) produced decline in left ventricular end-diastolic pressure (LVEDP) from 25.4 to 14.1 mm Hg (p less than 0.01) but modest increase in cardiac index (CI) from 2.41 to 3.02 L/min/m2 (P less than 0.05). Dopamine alone (6 microng/kg/min) caused an elevation of CI to 3.36 (P less than 0.01) but without decrease of LVEDP. Simultaneous infusion of the two agents resulted in favorable alterations in both hemodynamic variables: LVEDP decreased to 15.7 (P less than 0.01) and CI increased to 3.52 (P less than 0.01). It is concluded that dopamine substantially enhances the effectiveness of nitroprusside therapy in congestive heart failure by providing concomitantly the principal beneficial actions of the vasodilator and dopamine used separately. Thus combined dopamine with NP treatment considerably raises low CI while markedly reducing elevated LVEDP and provides a potentially efficacious pharmacologic modality for the treatment of severe congestive heart failure due to left ventricular dysfunction.

This article has been cited by other articles:

				E. C. H. Keung, S. J. Siskind, E. H. Sonneblick, H. S. Ribner, W. J. Schwartz, and T. H. LeJemtel Dobutamine Therapy in Acute Myocardial Infarction JAMA, January 9, 1981; 245(2): 144 - 146. [Abstract] [PDF]

				S. C. Babu, P. V. P. Sharma, A. Raciti, C. H. Mayr Jr, N. A. Elrabie, R. H. Clauss, W. M. Stahl, and L. R. M. Del Guercio Monitor-Guided Responses: Operability With Safety Is Increased in Patients With Peripheral Vascular Diseases Arch Surg, November 1, 1980; 115(11): 1384 - 1386. [Abstract] [PDF]

				P. Reyns, D. Romney, K. B. Desser, and A. Benchimol Serial Hemodynamic Studies During the Treatment of Congestive Heart Failure With Isolated Low-Dose Oral Prazosin Therapy Angiology, January 1, 1979; 30(12): 850 - 855. [Abstract] [PDF]

				G. L. Pierpont, J. N. Cohn, and J. A. Franciosa Congestive Cardiomyopathy: Pathophysiology and Response to Therapy Arch Intern Med, December 1, 1978; 138(12): 1847 - 1850. [Abstract] [PDF]